JP5697447B2 - アレルゲンに対する脱感作のためのペプチド - Google Patents
アレルゲンに対する脱感作のためのペプチド Download PDFInfo
- Publication number
- JP5697447B2 JP5697447B2 JP2010520628A JP2010520628A JP5697447B2 JP 5697447 B2 JP5697447 B2 JP 5697447B2 JP 2010520628 A JP2010520628 A JP 2010520628A JP 2010520628 A JP2010520628 A JP 2010520628A JP 5697447 B2 JP5697447 B2 JP 5697447B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- sequence
- peptides
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 429
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 275
- 239000013566 allergen Substances 0.000 title description 106
- 238000000586 desensitisation Methods 0.000 title description 11
- 239000000203 mixture Substances 0.000 claims abstract description 112
- 241000238711 Pyroglyphidae Species 0.000 claims abstract description 8
- 229940046533 house dust mites Drugs 0.000 claims abstract description 8
- 229920001184 polypeptide Polymers 0.000 claims description 136
- 208000010668 atopic eczema Diseases 0.000 claims description 29
- 230000000172 allergic effect Effects 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 15
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 4
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 4
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 12
- 208000026935 allergic disease Diseases 0.000 abstract description 10
- 230000007815 allergy Effects 0.000 abstract description 9
- 235000001014 amino acid Nutrition 0.000 description 73
- 150000001413 amino acids Chemical class 0.000 description 68
- 229960004784 allergens Drugs 0.000 description 59
- 108090000623 proteins and genes Proteins 0.000 description 47
- 239000002157 polynucleotide Substances 0.000 description 46
- 108091033319 polynucleotide Proteins 0.000 description 46
- 102000040430 polynucleotide Human genes 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 41
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 39
- 230000027455 binding Effects 0.000 description 39
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 39
- 235000018102 proteins Nutrition 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 38
- 238000000034 method Methods 0.000 description 36
- 239000000428 dust Substances 0.000 description 34
- 210000001744 T-lymphocyte Anatomy 0.000 description 32
- 239000013598 vector Substances 0.000 description 31
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 230000004044 response Effects 0.000 description 29
- 108091054438 MHC class II family Proteins 0.000 description 27
- 102000043131 MHC class II family Human genes 0.000 description 26
- 239000012634 fragment Substances 0.000 description 23
- 102000004127 Cytokines Human genes 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 22
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 19
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 description 18
- 108010061638 Dermatophagoides pteronyssinus antigen p 7 Proteins 0.000 description 17
- 208000035533 House dust allergy Diseases 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 description 14
- 208000006673 asthma Diseases 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 108700028369 Alleles Proteins 0.000 description 13
- 108010055622 Dermatophagoides farinae antigen f 1 Proteins 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 108010082995 Dermatophagoides farinae antigen f 2 Proteins 0.000 description 11
- 108010082990 Dermatophagoides farinae antigen f 7 Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 238000000159 protein binding assay Methods 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 102000003816 Interleukin-13 Human genes 0.000 description 9
- 108090000176 Interleukin-13 Proteins 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 238000012384 transportation and delivery Methods 0.000 description 9
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 8
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000016396 cytokine production Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 241000238876 Acari Species 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- -1 sulfide leukotrienes Chemical class 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 244000105624 Arachis hypogaea Species 0.000 description 5
- 244000281762 Chenopodium ambrosioides Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241000238713 Dermatophagoides farinae Species 0.000 description 5
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 235000020232 peanut Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 101100449439 Drosophila melanogaster grass gene Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000209082 Lolium Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 229940124277 aminobutyric acid Drugs 0.000 description 4
- 235000003484 annual ragweed Nutrition 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 235000006263 bur ragweed Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000003488 common ragweed Nutrition 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 235000009736 ragweed Nutrition 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 235000018185 Betula X alpestris Nutrition 0.000 description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 description 3
- 241001674044 Blattodea Species 0.000 description 3
- 241000218645 Cedrus Species 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 3
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 244000305267 Quercus macrolepis Species 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006058 immune tolerance Effects 0.000 description 3
- 238000000126 in silico method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000003614 tolerogenic effect Effects 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 102100026918 Phospholipase A2 Human genes 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical group CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical class N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000003659 bee venom Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000007622 bioinformatic analysis Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001712 encephalitogenic effect Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000013568 food allergen Substances 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000283084 Balaenoptera musculus Species 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 101100243820 Caenorhabditis elegans phlp-2 gene Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000723418 Carya Species 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 1
- 235000005490 Chenopodium botrys Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 244000052363 Cynodon dactylon Species 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010082996 Dermatophagoides farinae antigen f 4 Proteins 0.000 description 1
- 108010061612 Dermatophagoides pteronyssinus antigen p 3 Proteins 0.000 description 1
- 108010061569 Dermatophagoides pteronyssinus antigen p 4 Proteins 0.000 description 1
- 108010061573 Dermatophagoides pteronyssinus antigen p 5 Proteins 0.000 description 1
- 108010061636 Dermatophagoides pteronyssinus antigen p 6 Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000283087 Equus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000238739 Euroglyphus Species 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000854908 Homo sapiens WD repeat-containing protein 11 Proteins 0.000 description 1
- 241000441510 Hormodendrum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108010066345 MHC binding peptide Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000746981 Phleum Species 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 101000590737 Poa pratensis Pollen allergen KBG 31 Proteins 0.000 description 1
- 101000590736 Poa pratensis Pollen allergen KBG 41 Proteins 0.000 description 1
- 101000590741 Poa pratensis Pollen allergen KBG 60 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710171134 Protein Bet Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 244000124765 Salsola kali Species 0.000 description 1
- 235000007658 Salsola kali Nutrition 0.000 description 1
- 240000002751 Sideroxylon obovatum Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 240000006694 Stellaria media Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241001106462 Ulmus Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 241000218215 Urticaceae Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 241000256838 Vespula Species 0.000 description 1
- 102100020705 WD repeat-containing protein 11 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010004321 allergen Ves v 1 Proteins 0.000 description 1
- 108010004452 allergen Ves v 2 Proteins 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000003319 ant venom Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000013575 birch pollen allergen Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229920003211 cis-1,4-polyisoprene Polymers 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 102000019758 lipid binding proteins Human genes 0.000 description 1
- 108091016323 lipid binding proteins Proteins 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108010087487 myelin basic protein 85-99 Proteins 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000002578 wasp venom Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Insects & Arthropods (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0715949A GB0715949D0 (en) | 2007-08-15 | 2007-08-15 | Peptide with improved solubility |
| GB0715949.4 | 2007-08-15 | ||
| GB0716224.1 | 2007-08-20 | ||
| GB0716224A GB0716224D0 (en) | 2007-08-20 | 2007-08-20 | Peptides for vaccine |
| GB0723337A GB0723337D0 (en) | 2007-11-28 | 2007-11-28 | Peptide with reduced dimer formation |
| GB0723337.2 | 2007-11-28 | ||
| PCT/GB2008/002780 WO2009022156A2 (en) | 2007-08-15 | 2008-08-15 | Peptides for desensibilization against allergens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014204979A Division JP6040207B2 (ja) | 2007-08-15 | 2014-10-03 | アレルゲンに対する脱感作のためのペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010536333A JP2010536333A (ja) | 2010-12-02 |
| JP2010536333A5 JP2010536333A5 (cg-RX-API-DMAC7.html) | 2011-09-29 |
| JP5697447B2 true JP5697447B2 (ja) | 2015-04-08 |
Family
ID=40134075
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520628A Expired - Fee Related JP5697447B2 (ja) | 2007-08-15 | 2008-08-15 | アレルゲンに対する脱感作のためのペプチド |
| JP2014204979A Expired - Fee Related JP6040207B2 (ja) | 2007-08-15 | 2014-10-03 | アレルゲンに対する脱感作のためのペプチド |
| JP2016191563A Pending JP2017061455A (ja) | 2007-08-15 | 2016-09-29 | アレルゲンに対する脱感作のためのペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014204979A Expired - Fee Related JP6040207B2 (ja) | 2007-08-15 | 2014-10-03 | アレルゲンに対する脱感作のためのペプチド |
| JP2016191563A Pending JP2017061455A (ja) | 2007-08-15 | 2016-09-29 | アレルゲンに対する脱感作のためのペプチド |
Country Status (23)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| WO2009022155A2 (en) | 2007-08-15 | 2009-02-19 | Circassia Limited | Peptide with reduced dimer formation |
| US8821887B2 (en) | 2008-08-15 | 2014-09-02 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of IL-10 production |
| DK2153841T4 (en) * | 2008-08-15 | 2016-02-15 | Circassia Ltd | Vaccine comprising Amb a 1 peptides for use in the treatment of ambrosieallergi |
| GB0821806D0 (en) * | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| BRPI1008802A2 (pt) * | 2009-02-05 | 2016-03-08 | Circassia Ltd | composição, vetor e formulação farmacêutica para o uso na prevenção ou tratamento de alergia a pólen de grama por tolerização, produto, e, método in vitro para determinar se as células t reconhecem uma composição |
| KR101488902B1 (ko) * | 2009-10-08 | 2015-02-03 | 주식회사이언메딕스 | 실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도 |
| WO2011085783A1 (de) * | 2010-01-14 | 2011-07-21 | Merck Patent Gmbh | VARIANTEN DER GRUPPE 5-ALLERGENE DER SÜßGRÄSER MIT REDUZIERTER ALLERGENITÄT DURCH MUTAGENESE VON PROLINRESTEN |
| GB201002559D0 (en) * | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| WO2011151449A1 (en) * | 2010-06-03 | 2011-12-08 | Alk-Abelló A/S | Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof |
| EP2982684A1 (en) * | 2010-09-24 | 2016-02-10 | Maria R. Diaz-Torres | Peptides deriving from Alternaria Alternata major allergen Alt a 1 |
| EP2460824A1 (en) * | 2010-12-01 | 2012-06-06 | Biomay Ag | Hypoallergenic polypeptides for the treatment of house dust mite allergy |
| CN118078979A (zh) | 2011-04-29 | 2024-05-28 | 西莱克塔生物科技公司 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
| EP3299379A1 (en) * | 2011-06-15 | 2018-03-28 | ASIT BioTech S.A. | A method for the production of hydrolyzed allergens |
| CA2843274A1 (en) | 2011-07-29 | 2013-02-07 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
| GB201208293D0 (en) * | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| GB201209868D0 (en) * | 2012-06-01 | 2012-07-18 | Circassia Ltd | Alternaria peptides |
| GB201209862D0 (en) | 2012-06-01 | 2012-07-18 | Circassia Ltd | Cladosporium peptides |
| DK2914286T3 (da) | 2012-10-30 | 2021-11-08 | Aravax Pty Ltd | Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf |
| US10434088B2 (en) | 2013-05-03 | 2019-10-08 | Selecta Biosciences, Inc. | Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose |
| US20160130311A1 (en) * | 2013-06-05 | 2016-05-12 | Maria R. Diaz-Torres | T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy |
| HK1223019A1 (zh) * | 2013-06-06 | 2017-07-21 | Anergis Sa | 用於治疗室内尘蟎过敏的连续重叠肽 |
| JP7007534B2 (ja) * | 2013-09-25 | 2022-01-24 | アラヴァックス ピーティーワイ リミテッド | 新規免疫療法組成物およびその使用 |
| AU2014369866A1 (en) | 2013-12-23 | 2016-06-30 | Alk-Abello A/S | Peptide combinations and uses thereof in treating dust mite allergy |
| US9920101B2 (en) | 2014-03-31 | 2018-03-20 | Boehringer Ingelheim Vetmedica Gmbh | Modular antigen transportation molecules and uses therof |
| WO2016037165A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses |
| US11452774B2 (en) | 2015-02-20 | 2022-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10149904B2 (en) | 2015-02-20 | 2018-12-11 | The Board Of Trusteees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10166286B2 (en) | 2015-02-20 | 2019-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10143742B2 (en) | 2015-02-20 | 2018-12-04 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| JPWO2016159181A1 (ja) * | 2015-03-30 | 2018-02-22 | 国立大学法人大阪大学 | 免疫用ペプチド、免疫用ペプチドの製造方法、それを含む免疫疾患用医薬組成物、および免疫疾患の治療方法 |
| KR20180061338A (ko) * | 2015-09-30 | 2018-06-07 | 베링거잉겔하임베트메디카게엠베하 | 동물에서의 개선된 모듈러 항원 수송 분자 및 이의 용도 |
| KR101858840B1 (ko) | 2016-01-15 | 2018-05-16 | 단국대학교 천안캠퍼스 산학협력단 | 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제 |
| CA3055936A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| JP7300595B2 (ja) | 2017-07-18 | 2023-06-30 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 混合アレルゲン組成物の製造方法 |
| RU2020111503A (ru) * | 2017-09-18 | 2021-10-20 | Сутро Биофарма, Инк. | Конъюгаты антитела к рецептору фолиевой кислоты альфа и их применение |
| CN108078891B (zh) * | 2017-12-28 | 2021-05-07 | 昆明赛诺制药股份有限公司 | 一种含美洲大蠊精提物的保湿修复洗面奶 |
| CN107970199B (zh) * | 2018-01-03 | 2021-05-07 | 昆明赛诺制药股份有限公司 | 一种含美洲大蠊精提物的牙膏 |
| BR112021014486A2 (pt) | 2019-01-23 | 2021-09-28 | Before Brands, Inc. | Métodos para preparar composições de alérgenos mistas |
| CN117362453B (zh) * | 2023-12-08 | 2024-02-27 | 山东硕景生物科技有限公司 | 一种Derf1重组抗原、其制备方法及应用 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3174456D1 (en) | 1980-07-18 | 1986-05-28 | Du Pont | Monothioglycerol as thiol-protector in lyophilized materials |
| US4442212A (en) * | 1980-11-10 | 1984-04-10 | E. I. Du Pont De Nemours & Company | Monothioglycerol as thiol-protector in lyophilized materials |
| US5126399A (en) * | 1986-04-30 | 1992-06-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the preparation and use of site-directed immunologic reagents |
| US4906564A (en) * | 1987-03-13 | 1990-03-06 | The United States Of America As Represented By The Secretary Of The Army | Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens |
| EP0362290A4 (en) * | 1987-06-17 | 1991-09-25 | Princess Margaret Children's Medical Research Foundation (Inc.) | Cloning of mite allergens |
| FI891226A7 (fi) | 1988-04-28 | 1989-10-29 | The Board Of Trustees Of The Leland | Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon |
| GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
| ES2013359A6 (es) | 1988-11-04 | 1990-05-01 | Corporacion Biolog Farmaceutic | Procedimiento para la fabricacion de alergenos inmunogenicos polimerizados. |
| CA1340977C (en) | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5547669A (en) * | 1989-11-03 | 1996-08-20 | Immulogic Pharma Corp | Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I |
| AU650249B2 (en) | 1989-11-03 | 1994-06-16 | Immulogic Pharmaceutical Corporation | A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor |
| US6019972A (en) * | 1989-11-03 | 2000-02-01 | Immulogic Pharmaceutical Corporation | Peptides of human T cell reactive feline protein (TRFP) |
| US5433948A (en) * | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| DE69131131T2 (de) * | 1990-09-11 | 1999-10-14 | Institute For Child Health Research | Klonierung und sequenzierung von dermatophagoiden-antigenen (hausstaubmilben) |
| US5593698A (en) | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| JP2632603B2 (ja) | 1991-03-12 | 1997-07-23 | アサヒビール株式会社 | ヒト抗ＤｅｒｆＩＩＩｇＥ抗体が結合するペプチド |
| US6982326B1 (en) * | 1991-07-12 | 2006-01-03 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from Japanese cedar pollen |
| US6555116B1 (en) | 1991-10-12 | 2003-04-29 | Regents Of The University Of California | Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin |
| ES2334179T3 (es) * | 1991-10-16 | 2010-03-05 | Merck Patent Gmbh | Epitopes de celulas t de los alergenos principales de dermatofagoides (acaros del polvo domestico). |
| WO1994024281A1 (en) * | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| US7288256B1 (en) * | 1991-10-16 | 2007-10-30 | Merck Patent Gmbh | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| US6696061B1 (en) * | 1992-08-11 | 2004-02-24 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| EP0650976A4 (en) | 1992-08-14 | 1997-10-01 | Torii & Co Ltd | ALLERGEN PEPTIDE. |
| US5939283A (en) * | 1992-12-31 | 1999-08-17 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from dog dander and uses therefor |
| US5697103A (en) | 1993-01-11 | 1997-12-16 | Personal Expression I, Inc. | Therapeutic glove |
| NZ263913A (en) | 1993-03-12 | 1997-10-24 | Immulogic Pharma Corp | Lol pi protein allergen from ryegrass and related peptides coding sequences, vectors, protein production and use |
| US6849427B1 (en) * | 1993-03-12 | 2005-02-01 | Immulogic Pharmaceutical Corp. | Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor |
| JPH09501043A (ja) * | 1993-04-14 | 1997-02-04 | イミュロジク ファーマスーティカル コーポレイション | Ｄｅｒｍａｔｏｐｈａｇｏｉｄｅｓ（室内塵ダニ）由来の主要アレルゲンのｔ細胞エピトープ |
| WO1994027634A1 (en) | 1993-06-02 | 1994-12-08 | Institute For Child Health Research | Cryptic peptides for use in inducing immunologic tolerance |
| NZ271818A (en) | 1993-08-13 | 1997-11-24 | Immulogic Pharma Corp | T cell epitopes of ryegrass pollen antigen |
| US6180771B1 (en) * | 1993-12-08 | 2001-01-30 | Immulogic Pharmaceutical Corp. | Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor |
| JPH07215996A (ja) | 1994-01-31 | 1995-08-15 | Torii Yakuhin Kk | ダニアレルゲンのｂ細胞エピトープ |
| US5820862A (en) * | 1994-04-14 | 1998-10-13 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| ATE359296T1 (de) * | 1994-04-14 | 2007-05-15 | Merck Patent Gmbh | Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie |
| US6759234B1 (en) * | 1994-09-02 | 2004-07-06 | Immulogic Pharmaceutical Corporation | Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response |
| IL115744A (en) | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
| DE19508192A1 (de) * | 1995-03-09 | 1996-09-12 | Behringwerke Ag | Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung |
| DE19545662C2 (de) * | 1995-12-07 | 1998-11-26 | Mannesmann Sachs Ag | Selbstpumpendes hydropneumatisches Federbein mit innerer Niveauregulierung |
| DE69733343D1 (de) | 1996-03-21 | 2005-06-30 | Circassia Ltd | Kryptische peptide und verfahren zu ihrer identifizierung |
| EP1041996A4 (en) | 1997-12-22 | 2003-05-14 | Human Genome Sciences Inc | KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS |
| EP1044019A1 (en) | 1998-01-09 | 2000-10-18 | Circassia Limited | Methods and compositions for desensitisation |
| FR2806727A1 (fr) | 2000-03-23 | 2001-09-28 | Pf Medicament | Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable |
| ES2353347T3 (es) | 2000-08-21 | 2011-03-01 | Apitope Technology (Bristol) Limited | Péptido. |
| US7754686B2 (en) * | 2000-08-31 | 2010-07-13 | Novartis Vaccines And Diagnostics, Inc. | Stabilized FGF formulations containing reducing agents |
| CZ20031653A3 (en) * | 2000-11-16 | 2004-03-17 | Alk-Abelló A/S | Mutant allergens |
| US7786257B2 (en) | 2000-12-18 | 2010-08-31 | University Of Kansas | Signal-1/signal-2 bifunctional peptide inhibitors |
| US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| FR2820425B1 (fr) | 2001-02-08 | 2004-01-02 | Commissariat Energie Atomique | Melange de peptides issus d'une proteine nef et leurs applications |
| JP4812951B2 (ja) * | 2001-03-21 | 2011-11-09 | 一般財団法人化学及血清療法研究所 | 特異性不明のｔ細胞のクローン化法及びその認識ペプチドリガンドの同定方法 |
| GB0108752D0 (en) | 2001-04-06 | 2001-05-30 | Isis Innovation | Peptide epitopes and uses thereof |
| US20040202654A1 (en) | 2001-04-09 | 2004-10-14 | Mayo Foundation For Medical Education & Research | Methods and materials for cancer treatment |
| AUPR775401A0 (en) * | 2001-09-18 | 2001-10-11 | Monash University | Novel Epitopes and Uses Thereof |
| WO2003042344A2 (en) | 2001-11-13 | 2003-05-22 | Genentech, Inc. | Apo2 ligand/trail formulations |
| DE60229979D1 (cg-RX-API-DMAC7.html) * | 2001-12-05 | 2009-01-02 | Circassia Ltd | |
| AUPS148202A0 (en) * | 2002-04-02 | 2002-05-09 | Monash University | Immunotherapeutic and immunoprophylactic reagents |
| FR2841906B1 (fr) * | 2002-07-05 | 2006-08-18 | Stallergenes Sa | Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes |
| RU2324704C2 (ru) | 2002-07-17 | 2008-05-20 | Цитос Байотекнолоджи Аг | Молекулярные массивы антигенов |
| US20040071718A1 (en) * | 2002-09-18 | 2004-04-15 | Jaw-Ji Tsai | Local nasal immunotherapy for allergen-induced airway inflammation |
| US9493539B2 (en) | 2003-03-07 | 2016-11-15 | London Health Sciences Centre Research Inc. | Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases |
| US7541439B2 (en) | 2003-06-26 | 2009-06-02 | Merck Patent Gmbh | Thrombopoietin proteins with improved properties |
| GB0315754D0 (en) * | 2003-07-04 | 2003-08-13 | Univ Aberdeen | Pharmaceutical compositions |
| US20050053615A1 (en) * | 2003-07-16 | 2005-03-10 | Best Elaine A. | Variants of mite group 1 allergens for the treatment of house dust mite allergy |
| WO2005047323A1 (en) | 2003-11-10 | 2005-05-26 | Arriva-Prometic Inc. | Dry recombinant human alpha 1-antitrypsin formulation |
| WO2005103082A2 (en) | 2004-04-23 | 2005-11-03 | Novozymes A/S | Group 1 mite polypeptide variants |
| WO2005121166A1 (en) * | 2004-06-10 | 2005-12-22 | Monash University | Novel immunointeractive molecules and uses thereof |
| US20060029551A1 (en) | 2004-08-05 | 2006-02-09 | Kui Liu | Stable particle formulations of erythropoietin receptor agonists |
| JP4983258B2 (ja) | 2004-09-27 | 2012-07-25 | 株式会社林原 | イソサイクロマルトオリゴ糖及びイソサイクロマルトオリゴ糖生成酵素とそれらの製造方法並びに用途 |
| WO2006083906A2 (en) | 2005-02-01 | 2006-08-10 | Attenuon, Llc | Compositions containing the anti-angiogenic phscn-peptide |
| FR2881746B1 (fr) | 2005-02-07 | 2007-04-13 | Centre Nat Rech Scient | Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications |
| CA2621067C (en) | 2005-09-15 | 2014-04-29 | Alk-Abello A/S | A method for quantification of allergens |
| EP1829895A1 (en) * | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| GB0609121D0 (en) | 2006-05-09 | 2006-06-21 | Univ Birmingham | Peptide Therapy |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| JP5750600B2 (ja) * | 2006-08-11 | 2015-07-22 | ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルクＬｉｆｅ Ｓｃｉｅｎｃｅｓ Ｒｅｓｅａｒｃｈ Ｐａｒｔｎｅｒｓ Ｖｚｗ | 免疫原性ペプチドおよび免疫障害におけるその使用 |
| EP1958645A1 (en) | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
| US8148105B2 (en) | 2007-03-16 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Scaleable manufacturing process for cysteine endoprotease B, isoform 2 |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| WO2009022155A2 (en) * | 2007-08-15 | 2009-02-19 | Circassia Limited | Peptide with reduced dimer formation |
| WO2009067191A2 (en) | 2007-11-16 | 2009-05-28 | The General Hospital Corporation | Methods and compositions for the treatment of hepatitis c virus (hcv) infection |
| GB2455108A (en) | 2007-11-28 | 2009-06-03 | Circassia Ltd | T-Cell dependent method for detecting non-allergic or intrinsic disorders |
-
2008
- 2008-08-15 WO PCT/GB2008/002779 patent/WO2009022155A2/en not_active Ceased
- 2008-08-15 EP EP11178181.1A patent/EP2397154B1/en not_active Not-in-force
- 2008-08-15 US US12/673,334 patent/US8551493B2/en not_active Expired - Fee Related
- 2008-08-15 CN CN2008801116120A patent/CN101820907B/zh not_active Expired - Fee Related
- 2008-08-15 WO PCT/GB2008/002778 patent/WO2009022154A2/en not_active Ceased
- 2008-08-15 EP EP08788348A patent/EP2083856B1/en not_active Not-in-force
- 2008-08-15 DK DK08788348.4T patent/DK2083856T3/da active
- 2008-08-15 KR KR1020107005503A patent/KR101699554B1/ko not_active Expired - Fee Related
- 2008-08-15 HR HRP20130270AT patent/HRP20130270T1/hr unknown
- 2008-08-15 US US12/673,412 patent/US8652485B2/en active Active
- 2008-08-15 AT AT08788348T patent/ATE482721T1/de active
- 2008-08-15 WO PCT/GB2008/002781 patent/WO2009022157A2/en not_active Ceased
- 2008-08-15 ES ES08788347T patent/ES2402956T3/es active Active
- 2008-08-15 NZ NZ583362A patent/NZ583362A/en not_active IP Right Cessation
- 2008-08-15 NZ NZ583361A patent/NZ583361A/xx not_active IP Right Cessation
- 2008-08-15 HR HR20100662T patent/HRP20100662T1/hr unknown
- 2008-08-15 EA EA201070271A patent/EA023303B1/ru not_active IP Right Cessation
- 2008-08-15 DK DK08788347.6T patent/DK2190473T3/da active
- 2008-08-15 BR BRPI0815395-7A2A patent/BRPI0815395A2/pt not_active IP Right Cessation
- 2008-08-15 MX MX2010001779A patent/MX2010001779A/es active IP Right Grant
- 2008-08-15 CA CA2696563A patent/CA2696563A1/en not_active Abandoned
- 2008-08-15 PT PT111781811T patent/PT2397154E/pt unknown
- 2008-08-15 DE DE602008002810T patent/DE602008002810D1/de active Active
- 2008-08-15 CN CN201310140326.XA patent/CN103272227B/zh not_active Expired - Fee Related
- 2008-08-15 SI SI200830119T patent/SI2083856T1/sl unknown
- 2008-08-15 PL PL08788348T patent/PL2083856T3/pl unknown
- 2008-08-15 AU AU2008288283A patent/AU2008288283B2/en not_active Ceased
- 2008-08-15 WO PCT/GB2008/002780 patent/WO2009022156A2/en not_active Ceased
- 2008-08-15 US US12/673,386 patent/US9340580B2/en not_active Expired - Fee Related
- 2008-08-15 EA EA201070270A patent/EA018110B1/ru not_active IP Right Cessation
- 2008-08-15 JP JP2010520628A patent/JP5697447B2/ja not_active Expired - Fee Related
- 2008-08-15 EP EP08788347A patent/EP2190473B1/en not_active Revoked
- 2008-08-15 SI SI200830933T patent/SI2190473T1/sl unknown
- 2008-08-15 PT PT08788348T patent/PT2083856E/pt unknown
- 2008-08-15 EP EP10006685A patent/EP2286833A3/en not_active Withdrawn
-
2010
- 2010-02-12 ZA ZA2010/01056A patent/ZA201001056B/en unknown
- 2010-02-12 ZA ZA2010/01054A patent/ZA201001054B/en unknown
- 2010-02-14 IL IL203943A patent/IL203943A/en not_active IP Right Cessation
- 2010-12-07 CY CY20101101127T patent/CY1110981T1/el unknown
-
2013
- 2013-08-23 US US13/974,603 patent/US20130336999A1/en not_active Abandoned
-
2014
- 2014-01-08 US US14/150,045 patent/US20140186403A1/en not_active Abandoned
- 2014-10-03 JP JP2014204979A patent/JP6040207B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-07 CY CY20151100901T patent/CY1116828T1/el unknown
-
2016
- 2016-04-11 US US15/095,480 patent/US20160289281A1/en not_active Abandoned
- 2016-09-29 JP JP2016191563A patent/JP2017061455A/ja active Pending
- 2016-10-17 US US15/294,973 patent/US9744222B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6040207B2 (ja) | アレルゲンに対する脱感作のためのペプチド | |
| JP5857002B2 (ja) | 猫アレルギーに対するワクチンペプチド併用剤 | |
| JP5788319B2 (ja) | ブタクサアレルギーの治療用のＡｍｂａ１ペプチド | |
| JP6215252B2 (ja) | ワクチン用ペプチド | |
| AU2013203568B2 (en) | Peptides for desensibilization against allergens | |
| HK1164700B (en) | Peptides for desensibilization against allergens | |
| HK1132194B (en) | Peptides for desensibilization against allergens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110812 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130911 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141118 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141211 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150210 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5697447 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |